Iron chelation therapy in myelodysplastic syndromes: Where do we stand?

Expert Review of Hematology

Volumn 6, Issue 4, 2013, Pages 397-410

  Mitchell, Mhairi ^a   Gore, Steven D ^b   Zeidan, Amer M ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

anemia; iron chelation therapy; iron overload; myelodysplastic syndromes; transfusion dependency

Indexed keywords

CHELATION THERAPY; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84885895558     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.814456     Document Type: Review

References (102)

1. Steensma DP. The role of iron chelation therapy for patients with myelodysplastic syndromes. J. Natl Compr. Canc. Netw. 9(1), 65-75 (2011).
2. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk. Res. 31 (Suppl. 3), S2-S6 (2007).
3. Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 23(30), 7594-7603 (2005).
4. Takatoku M, Uchiyama T, Okamoto S et al.; Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur. J. Haematol. 78(6), 487-494 (2007).
5. Rose C, Brechignac S, Vassilief D et al.; Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk. Res. 34(7), 864-870 (2010).
6. Raptis A, Duh MS, Wang ST et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 50(1), 190-199 (2010).
7. Leitch HA. Controversies surrounding iron chelation therapy for MDS. Blood Rev. 25(1), 17-31 (2011).
8. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk. Res. 31 Suppl. 3, S7-S9 (2007).
9. Leitch HA. Iron chelation therapy in MDS: does it improve survival? Leuk. Res. 34(7), 852-853 (2010).
10. Leitch HA, Vickars LM. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? Hematology Am. Soc. Hematol. Educ. Program 664-672 (2009).
11. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 114(26), 5251-5255 (2009).
12. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int. J. Hematol. 88(1), 24-29 (2008).
13. Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J. Natl. Compr. Canc. Netw. 9(1), 57-63 (2011).
14. Ma X. Epidemiology of myelodysplastic syndromes. Am. J. Med. 125(7 Suppl.), S2-S5 (2012).
15. Greenberg PL, Attar E, Bennett JM et al.; NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J. Natl Compr. Canc. Netw. 9(1), 30-56 (2011).
16. Zeidan A, Faltas BD, Smith B, et al. Myelodysplastic syndromes: what do hospitalists need to know? J. Hosp. Med. doi:10.1002/jhm.2049 (2013) (Epub ahead of print).
17. Zeidan AM, Smith BD, Komrokji RS, et al. Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS). Am. J. Med. 126(4), e25 (2013).
18. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6), 2079-2088 (1997).
19. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12), 2454-2465 (2012).
20. Mufti GJ, Potter V. Myelodysplastic syndromes: who and when in the course of disease to transplant. Hematology Am. Soc. Hematol. Educ. Program 2012, 49-55 (2012).
21. Malcovati L. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes. Clin. Lymphoma Myeloma 9 Suppl. 3, S305-S311 (2009).
22. Bennett JM; MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am. J. Hematol. 83(11), 858-861 (2008).
23. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am. J. Hematol. 83(10), 765-770 (2008).
24. Davidoff AJ, Weiss Smith S, Baer MR et al. Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. Haematologica 97(1), 128-132 (2012).
25. Fenaux P, Giagounidis A, Selleslag D et al.; A randomized Phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118(14), 3765-3776 (2011).
26. List A, Dewald G, Bennett J et al.; Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355(14), 1456-1465 (2006).
27. Oliva EN, Schey C, Hutchings AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am. J. Blood Res. 1(2), 160-166 (2011).
28. Malcovati L, Della Porta MG, Strupp C et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 96(10), 1433-1440 (2011).
29. Goldberg SL, Chen E, Corral M et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J. Clin. Oncol. 28(17), 2847-2852 (2010).
30. Andrews NC, Schmidt PJ. Iron homeostasis. Annu. Rev. Physiol. 69, 69-85 (2007).
31. Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic syndromes. Leuk. Lymphoma 49(3), 427-438 (2008).
32. Wells RA, Leber B, Buckstein R et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk. Res. 32(9), 1338-1353 (2008).
33. Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am. Soc. Hematol. Educ. Program 166-175 (2008).
34. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N. Engl. J. Med. 364(2), 146-156 (2011).
35. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102(7), 2670-2677 (2003).
36. Invernizzi R. Iron overload, oxidative damage and ineffective erythropoiesis in myelodysplastic syndromes. Eur. Haematol. 4, 34-38 (2010).
37. Varkonyi J, Tarkovacs G, Karadi I et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol. 109(2), 64-67 (2003).
38. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 95(8), 1433-1434 (2010).
39. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int. J. Hematol. 76(3), 219-228 (2002).
40. Messa E, Carturan S, Maffe C et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 95(8), 1308-1316 (2010).
41. Konen E, Ghoti H, Goitein O et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am. J. Hematol. 82(11), 1013-1016 (2007).
42. Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int. J. Hematol. 77(4), 342-350 (2003).
43. List AF, Baer MR, Steensma DP et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusiondependent patients with myelodysplastic syndrome. J. Clin. Oncol. 30(17), 2134-2139 (2012).
44. Chan LSA, Buckstein R. Reis MD et al. Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML? Blood 112(11), 928 (2008).
45. Chan LSA, Gu LC, Rauh MJ, Wells RA. Iron overload accelerates development of leukaemia: evidence from a mouse model. ASH Annual Meeting Abstracts 116(21), 122 (2010).
46. Hartmann J, Braulke F, Sinzig U et al. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk. Res. 37(3), 327-332 (2013).
47. Sekeres MA, Schoonen WM, Kantarjian H et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J. Natl Cancer Inst. 100(21), 1542-1551 (2008).
48. Steensma DP. Myelodysplasia paranoia: iron as the new radon. Leuk. Res. 33(9), 1158-1163 (2009).
49. Chacko J, Pennell DJ, Tanner MA et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br. J. Haematol. 138(5), 587-593 (2007).
50. Gattermann N. Pathophysiological and clinical aspects of iron chelation therapy in MDS. Curr. Pharm. Des. 18(22), 3222-3234 (2012).
51. Di Tucci AA, Matta G, Deplano S et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 93(9), 1385-1388 (2008).
52. Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am. J. Hematol. 83(8), 611-613 (2008).
53. Remacha AF, Arrizabalaga B, Del Canizo C, Sanz G, Villegas A. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Ann. Hematol. 89(2), 147-154 (2010).
54. Sanz G, Nomdedeu B, Such E et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 112, 238-239 (2008).
55. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr. Med. Res. Opin. 25(1), 139-147 (2009).
56. Steensma DP. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate. Curr. Hematol. Malig. Rep. 6(2), 136-144 (2011).
57. Dayyani F, Conley AP, Strom SS et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 116(9), 2174-2179 (2010).
58. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann. NY. Acad. Sci. 850, 191-201 (1998).
59. Au W, Lam W, Chu W et al. A pilot MRI study of organ specific hemosiderosis and functional correlation in Chinese patients with myelodysplasia and aplastic anemia with raised ferritin levels. Hematol. Oncol. 26(4), 225-228 (2008).
60. Lu JP, Hayashi K. Selective iron deposition in pancreatic islet B cells of transfusional iron-overloaded autopsy cases. Pathol. Int. 44(3), 194-199 (1994).
61. Nairz M, Schroll A, Sonnweber T, Weiss G. The struggle for iron-a metal at the host-pathogen interface. Cell. Microbiol. 12(12), 1691-1702 (2010).
62. Pullarkat V, Blanchard S, Tegtmeier B et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 42(12), 799-805 (2008).
63. Ozyilmaz E, Aydogdu M, Sucak G et al. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 45(10), 1528-1533 (2010).
64. Armand P, Kim HT, Cutler CS et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 14(1), 28-35 (2008).
65. Alessandrino EP, Della Porta MG, Bacigalupo A et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 95(3), 476-484 (2010).
66. Armand P, Sainvil MM, Kim HT et al. Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 48(1), 146-147 (2013).
67. Mahindra A, Bolwell B, Sobecks R et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br. J. Haematol. 146(3), 310-316 (2009).
68. Platzbecker U, Bornhauser M, Germing U et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol. Blood Marrow Transplant. 14(11), 1217-1225 (2008).
69. Lim ZY, Fiaccadori V, Gandhi S et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk. Res. 34(6), 723-727 (2010).
70. Mast AE, Field JJ. Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome. Transfusion 52(10), 2078-2080 (2012).
71. Durairaj S, Chew S, Hyslop A, Keenan N, Groves MJ, Tauro S. Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates. Am. J. Hematol. 86(5), 406-410 (2011).
72. Gattermann N, Finelli C, Porta MD et al.; Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk. Res. 34(9), 1143-1150 (2010).
73. Cermak J, Jonasova A, Vondrakova J et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin 35(3), 217-227 (2011).
74. Leitch HA, Leger CS, Goodman TA et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin. Leuk. 2, 205-211 (2008).
75. Neukirchen J, Fox F, Kundgen A et al. Improved survival in MDS patients receiving iron chelation therapy-a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk. Res. 36(8), 1067-1070 (2012).
76. Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk. Res. (2012).
77. Gattermann N, Jarisch A, Schlag R et al. Deferasirox treatment of iron-overloaded chelation-naive and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. Eur. J. Haematol. 88(3), 260-268 (2012).
78. Breccia M, Finsinger P, Loglisci G et al. Deferasirox treatment for myelodysplastic syndromes: 'real-life' efficacy and safety in a single-institution patient population. Ann. Hematol. 91(9), 1345-1349 (2012).
79. Nolte F, Hochsmann B, Giagounidis A et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann. Hematol. 92(2), 191-198 (2013).
80. Metzgeroth G, Dinter D, Schultheis B et al. Deferasirox in MDS patients with transfusion-caused iron overload-a Phase-II study. Ann. Hematol. 88(4), 301-310 (2009).
81. Gattermann N, Finelli C, Della Porta M et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 97(9), 1364-1371 (2012).
82. Angelucci E, Santini V, Di Tucci AA et al. Deferasirox chelation therapy in transfusion dependent MDS patients. Final report from the Gimema MDS0306 Prospective Trial. ASH Annual Meeting and Exposition (2012).
83. Messa E, Cilloni D, Saglio G. Iron chelation therapy in myelodysplastic syndromes. Adv. Hematol. 2010, 756289 (2010).
84. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr. Opin. Infect. Dis. 21(6), 620-625 (2008).
85. Lee JW, Kang HJ, Kim EK, Kim H, Shin HY, Ahn HS. Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant. 44(12), 793-797 (2009).
86. Greenberg PL, Koller CA, Cabantchik ZI et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk. Res. 34(12), 1560-1565 (2010).
87. Kikuchi S, Kobune M, Iyama S et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic. Biol. Med. 53(4), 643-648 (2012).
88. Guariglia R, Martorelli MC, Villani O et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk. Res. 35(5), 566-570 (2011).
89. Fibach E, Rachmilewitz EA. Selective toxicity towards myelodysplastic hematopoietic progenitors-another rationale for iron chelation in MDS. Leuk. Res. 36(8), 962-963 (2012).
90. Pullarkat V, Sehgal A, Li L et al. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors. Leuk. Res. 36(8), 966-973 (2012).
91. Delforge M, Selleslag D, Triffet A et al. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. Ann. Hematol. 90(6), 655-666 (2011).
92. Giagounidis A, Leto di Priolo S, Ille S, Fenaux P. A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS. Ann. Hematol. 90(6), 667-673 (2011).
93. Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J. Natl Compr. Canc. Netw. 6(9), 942-953 (2008).
94. Faltas B, Zeidan A, Gergis U. Myelodysplastic syndromes: towards a risk-adaptive treatment approach. Expert. Rev. Hematol. (In Press).
95. Zeidan A, Linhares Y, Gore S. Current therapy for myelodysplastic syndromes. Blood Rev. (In Press).
96. Santini V, Alessandrino PE, Angelucci E et al.; Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk. Res. 34(12), 1576-1588 (2010).
97. Bowen D, Culligan D, Jowitt S et al.; Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol. 120(2), 187-200 (2003).
98. Greenberg PL, Rigsby CK, Stone RM et al. NCCN Task Force: transfusion and iron overload in patients with myelodysplastic syndromes. J. Natl Compr. Canc. Netw. 7(Suppl. 9), S1-16 (2009).
99. Arrizabalaga B, del Cañizo C, Remacha A, Sanz G, Villegas A. Guía clínica de quelación del paciente con síndrome mielodisplásico [Clinical guide to chelation therapy for patients with myelodysplastic syndrome (Spanish Guidelines)]. Haematologica 93(Suppl. 1), 3-10 (2008).
100. Mittelman M, Lugassy G, Merkel D et al.; Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines. Isr. Med. Assoc. J. 10(5), 374-376 (2008).
101. Suzuki T, Tomonaga M, Miyazaki Y et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int. J. Hematol. 88(1), 30-35 (2008).
102. Valent P, Krieger O, Stauder R et al. Iron overload in myelodysplastic syndromes (MDS)-diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur. J. Clin. Invest. 38(3), 143-149 (2008).